王长洪教授治疗腹泻型肠易激综合征学术经验研究
|
摘要
腹泻型肠易激综合征发病和病机的理论研究:论文首先总结了祖国医学对腹泻型肠易激综合征(D-IBS)的认识,包括对症状、病名及病位描述、病因病机及证治沿革和当代中医对D-IBS病因和发病机制的认识;继之对西医学对D-IBS病因和发病机制的认识做一简述,最后将导师对D-IBS发病和病机的认识和创新进行阐述。导师认为脾胃虚弱为致病之本,肝脾不调为病机关键,脾肾两虚是重要的病机演化。从而导师认为脾胃虚弱、肝脾不调、脾肾阳虚在D-IBS发病中几乎具有同等的地位,因此,导师治疗中从分析基本病机入手,肝脾肾同调成为导师治疗D-IBS的重要治疗方法,也是导师治疗该病的创新之所在。
王长洪教授治疗腹泻型肠易激综合征学术思想总结:王长洪教授在治疗D-IBS方面积累了大量的临床经验。王长洪教授根据D-IBS的病机特点,临证常施以疏肝健脾法、健脾燥湿法、温肾固本法、肝脾肾同调等法,并依据病机演变灵活应用,临证施治又有斟酌变化。治疗中同时注重患者情志的调摄和心理疏导及饮食的调理。王教授在治疗慢性泄泻用药方面独具自己的用药规律,如温清并举,主从有别;温燥勿过,贵在相宜;宜通少涩,贵在有度;久泻不止,酌用渗利等,并喜用多组药对。
健脾调肝温肾方治疗腹泻型肠易激综合征的临床研究:本试验选择D-IBS患者80例进行前瞻性随机、西药治疗平行对照的临床试验。治疗组和对照组各40例,治疗组口服健脾调肝温肾方,对照组口服匹维溴铵片。观察及检测项目:(1)观察并记录治疗前、治疗第14天和28天腹痛或腹部不适、大便情况及伴随的相关症状;(2)检测治疗前后直肠敏感性;(3)应用SF-36和IBS-00L对患者的生活质量进行测评。停药4周后对治愈和显效病人进行随访。结果发现,腹痛或腹部不适、腹胀及排便急迫感在治疗的各时点记分,组间差别均无统计学意义;大便次数和大便性状在治疗过程中各时点记分,组间差别无统计学意义,但对PPS分析,第28天记分下降值两组间差别有统计学意义(P＜0.05),治疗组优于对照组;粘液便在治疗的第28天,两组间记分差别有统计学意义,治疗组优于对照组。各症状的两组终点记分与基线比较的差别均有高度统计学意义。综合疗效:PPS:治疗组和对照组的痊愈率为24.32%v19.44%,总有效率为81.08%v80.56%;FAS:治疗组和对照组的痊愈率为22.50%v1 7.5%,总有效率为80.00%v77.50%,两组比较无显著统计学意义。远期疗效:对两组痊愈和显效的病例随访,治疗组和对照组分别有4例和12例复发或加重,两组间有显著差异(P＜0.05)。直肠敏感性的变化:治疗后,治疗组和对照组的直肠感知阈值、排便阈值和疼痛阈值均有改善,且有统计学意义(P＜0.05)。生活质量:SF-36:治疗后,治疗组在躯体疼痛、总体健康、活力、社会功能和心理健康方面的积分均有明显提高(P＜0.05);治疗组在躯体疼痛、心理健康和社会功能方面的疗效优于对照组(P＜0.05)。IBS-QOL:治疗后,治疗组患者的烦躁焦虑、健康担忧、饮食限制、社会反应及人际关系方面积分均有显著改善(P＜0.05);治疗组在改善烦躁焦虑、人际关系方面疗效优于对照组(P＜0.05)。因此,通过本实验研究认为,健脾调肝温肾方治疗D-IBS有效,且在改善大便次数、性状及粘液便方面优于匹维溴铵片,在远期疗效方面也优于匹维溴铵,同时可改善患者生活质量。治疗机理可能通过调整肠道敏感性而起作用。该方值得进一步研究开发及推广应用。
The theoretical study of etiopathogenisis and pathogenesis on diarrheapredominant irritable bowel syndrom(D-IBS):This article discuss the etiopathogenisis and pathogenesis of D-IBS from three directions:Traditional Chinese medicine,Western medicine and professor wang-changhong's.Professor Wang considered that D-IBS had the intimate relationship with liver,spleen and kidney and regard that weakness of the spleen and stomach is the foundation of pathopoiesis,hepatosplenic disorder is the key point of pathogenesis,asthenia of both the spleen and kidney is the important pathogenesis evolution.
Academic thought of professor wang-changhong in treating D-IBS: Professor wang had accumulated experience of treatment on D-IBS.Invigorate the spleen and coordinating liver,invigorate the spleen and deprive the evil wetness,warming the kidney and firm the foundation and regulating the functions of Liver,Spleen and Kidney at the same time were important means of professor wang treating D-IBS.Professor Wang likes to use the method of regulating the functions of Liver,Spleen and Kidney at the same time best clinically.Professor Wang always following the rule of medication on D-IBS as follows:warming and clearing hot Simultaneously;to deprive the evil wetness,the method of warm should be administered,but should not warm too much;promoting blood flow and dissipate phlegm should be apply if the course last long time,and so on.
The clinical study of jianpitiaoganwenshenfangon D-IBS:We verify the efficacy of jianpitiaoganwenshenfang(JTW) on D-IBS with the researching of clinical,and analysis the treatment mechanism of JTWS on D-IBS with observating the influence of JTW on rectal sensitivity.A prospective,randomized controlled trial was conducted.80 patients were divided into 2 groups randomly. Treatment group(n=40) took the JTW,control group(n=40) took pinaverium bromide tablet.The therapeutic course for both groups was 4 weeks.Items should be observed or detected as follows:(1) observe and record the symptom of D-IBS at pretherapy,the 14~(th) day and the 28~(th) day;(2)detect the rectum sensitivity at before and after treatment;(3)survey the quality of life by SF-36 and IBS-QOL at before and after treatment.After drug withdrawal 4 weeks,followed up the patients that cured and excellence.Improving of symptom:There no statistical significance between two group on scores of abdominal pain or abdominal discomfort,abdominal distention and defecation urgency at 14~(th) day and 28~(th) day. The difference on score of degression at 14~(th) day and 28~(th) day hadn't statistical significance;there no statistical significance between two group on scores of frequency of defecation and character of defecation at 14~(th) day and 28~(th) day.PPS analysis showed that the difference of score of degression at 28~(th) day had the statistical significance(P＜0.05),treatment group was better than control group;the difference of the score of mucus stool at 28~(th) day had the statistical significance( P＜0.05) too,treatment group was better than control group.The scores of every symptom of end point were different from of baseline statistically,therapeutic effect of synthetic:FAS analysis showed that the total effective rates of the treatment group and the controlled group were 80.00%and 77.50%respectively (P＞0.05).PPS analysis showed that they were 81.08%and 80.56%respectively (P＞0.05).No significant difference between two groups was detected.Protective efficacy:he patients that cured and excellence were followed up after drug withdrawal.There were 4 cases and 12 cases recidivating or aggravation in treatment group and control group respectively.There is significant difference on recurrence rates between two group(P＜0.05).quality of life:SF-36:the accumulated points on bodily pain,general health,vitality,social functioning and mental health increased significantly in treatment group after treatment(P＜0.05) .treatment group is better than control group on improving bodily pain,mental health and social functioning(P＜0.05)。IBS-QOL:the accumulated points on dysphoria,food avoidance,health worry,social reaction and relationship increased significantly in treatment group after treatment(P＜0.05).treatment group is better than control group on improving dysphoria and relationship( P＜0.05).JTW is effective in treating D-IBS and better than pinaverium bromide tablet on improving frequency and character of stool,mucus stool.Its prostective efficacy is better than pinaverium bromide tablet too.Meanwhile,it can improve patients' quality of life.The mechanism of treatment is adjusting the sensitivity of intestines.JTW is worth investigating and generalization.
王长洪教授治疗腹泻型肠易激综合征学术思想总结:王长洪教授在治疗D-IBS方面积累了大量的临床经验。王长洪教授根据D-IBS的病机特点,临证常施以疏肝健脾法、健脾燥湿法、温肾固本法、肝脾肾同调等法,并依据病机演变灵活应用,临证施治又有斟酌变化。治疗中同时注重患者情志的调摄和心理疏导及饮食的调理。王教授在治疗慢性泄泻用药方面独具自己的用药规律,如温清并举,主从有别;温燥勿过,贵在相宜;宜通少涩,贵在有度;久泻不止,酌用渗利等,并喜用多组药对。
健脾调肝温肾方治疗腹泻型肠易激综合征的临床研究:本试验选择D-IBS患者80例进行前瞻性随机、西药治疗平行对照的临床试验。治疗组和对照组各40例,治疗组口服健脾调肝温肾方,对照组口服匹维溴铵片。观察及检测项目:(1)观察并记录治疗前、治疗第14天和28天腹痛或腹部不适、大便情况及伴随的相关症状;(2)检测治疗前后直肠敏感性;(3)应用SF-36和IBS-00L对患者的生活质量进行测评。停药4周后对治愈和显效病人进行随访。结果发现,腹痛或腹部不适、腹胀及排便急迫感在治疗的各时点记分,组间差别均无统计学意义;大便次数和大便性状在治疗过程中各时点记分,组间差别无统计学意义,但对PPS分析,第28天记分下降值两组间差别有统计学意义(P＜0.05),治疗组优于对照组;粘液便在治疗的第28天,两组间记分差别有统计学意义,治疗组优于对照组。各症状的两组终点记分与基线比较的差别均有高度统计学意义。综合疗效:PPS:治疗组和对照组的痊愈率为24.32%v19.44%,总有效率为81.08%v80.56%;FAS:治疗组和对照组的痊愈率为22.50%v1 7.5%,总有效率为80.00%v77.50%,两组比较无显著统计学意义。远期疗效:对两组痊愈和显效的病例随访,治疗组和对照组分别有4例和12例复发或加重,两组间有显著差异(P＜0.05)。直肠敏感性的变化:治疗后,治疗组和对照组的直肠感知阈值、排便阈值和疼痛阈值均有改善,且有统计学意义(P＜0.05)。生活质量:SF-36:治疗后,治疗组在躯体疼痛、总体健康、活力、社会功能和心理健康方面的积分均有明显提高(P＜0.05);治疗组在躯体疼痛、心理健康和社会功能方面的疗效优于对照组(P＜0.05)。IBS-QOL:治疗后,治疗组患者的烦躁焦虑、健康担忧、饮食限制、社会反应及人际关系方面积分均有显著改善(P＜0.05);治疗组在改善烦躁焦虑、人际关系方面疗效优于对照组(P＜0.05)。因此,通过本实验研究认为,健脾调肝温肾方治疗D-IBS有效,且在改善大便次数、性状及粘液便方面优于匹维溴铵片,在远期疗效方面也优于匹维溴铵,同时可改善患者生活质量。治疗机理可能通过调整肠道敏感性而起作用。该方值得进一步研究开发及推广应用。
The theoretical study of etiopathogenisis and pathogenesis on diarrheapredominant irritable bowel syndrom(D-IBS):This article discuss the etiopathogenisis and pathogenesis of D-IBS from three directions:Traditional Chinese medicine,Western medicine and professor wang-changhong's.Professor Wang considered that D-IBS had the intimate relationship with liver,spleen and kidney and regard that weakness of the spleen and stomach is the foundation of pathopoiesis,hepatosplenic disorder is the key point of pathogenesis,asthenia of both the spleen and kidney is the important pathogenesis evolution.
Academic thought of professor wang-changhong in treating D-IBS: Professor wang had accumulated experience of treatment on D-IBS.Invigorate the spleen and coordinating liver,invigorate the spleen and deprive the evil wetness,warming the kidney and firm the foundation and regulating the functions of Liver,Spleen and Kidney at the same time were important means of professor wang treating D-IBS.Professor Wang likes to use the method of regulating the functions of Liver,Spleen and Kidney at the same time best clinically.Professor Wang always following the rule of medication on D-IBS as follows:warming and clearing hot Simultaneously;to deprive the evil wetness,the method of warm should be administered,but should not warm too much;promoting blood flow and dissipate phlegm should be apply if the course last long time,and so on.
The clinical study of jianpitiaoganwenshenfangon D-IBS:We verify the efficacy of jianpitiaoganwenshenfang(JTW) on D-IBS with the researching of clinical,and analysis the treatment mechanism of JTWS on D-IBS with observating the influence of JTW on rectal sensitivity.A prospective,randomized controlled trial was conducted.80 patients were divided into 2 groups randomly. Treatment group(n=40) took the JTW,control group(n=40) took pinaverium bromide tablet.The therapeutic course for both groups was 4 weeks.Items should be observed or detected as follows:(1) observe and record the symptom of D-IBS at pretherapy,the 14~(th) day and the 28~(th) day;(2)detect the rectum sensitivity at before and after treatment;(3)survey the quality of life by SF-36 and IBS-QOL at before and after treatment.After drug withdrawal 4 weeks,followed up the patients that cured and excellence.Improving of symptom:There no statistical significance between two group on scores of abdominal pain or abdominal discomfort,abdominal distention and defecation urgency at 14~(th) day and 28~(th) day. The difference on score of degression at 14~(th) day and 28~(th) day hadn't statistical significance;there no statistical significance between two group on scores of frequency of defecation and character of defecation at 14~(th) day and 28~(th) day.PPS analysis showed that the difference of score of degression at 28~(th) day had the statistical significance(P＜0.05),treatment group was better than control group;the difference of the score of mucus stool at 28~(th) day had the statistical significance( P＜0.05) too,treatment group was better than control group.The scores of every symptom of end point were different from of baseline statistically,therapeutic effect of synthetic:FAS analysis showed that the total effective rates of the treatment group and the controlled group were 80.00%and 77.50%respectively (P＞0.05).PPS analysis showed that they were 81.08%and 80.56%respectively (P＞0.05).No significant difference between two groups was detected.Protective efficacy:he patients that cured and excellence were followed up after drug withdrawal.There were 4 cases and 12 cases recidivating or aggravation in treatment group and control group respectively.There is significant difference on recurrence rates between two group(P＜0.05).quality of life:SF-36:the accumulated points on bodily pain,general health,vitality,social functioning and mental health increased significantly in treatment group after treatment(P＜0.05) .treatment group is better than control group on improving bodily pain,mental health and social functioning(P＜0.05)。IBS-QOL:the accumulated points on dysphoria,food avoidance,health worry,social reaction and relationship increased significantly in treatment group after treatment(P＜0.05).treatment group is better than control group on improving dysphoria and relationship( P＜0.05).JTW is effective in treating D-IBS and better than pinaverium bromide tablet on improving frequency and character of stool,mucus stool.Its prostective efficacy is better than pinaverium bromide tablet too.Meanwhile,it can improve patients' quality of life.The mechanism of treatment is adjusting the sensitivity of intestines.JTW is worth investigating and generalization.
引文
[1]Agreus L,Svardsudd K,Nyren O,et al.Irritable bowel syndrome and dyspepsia in the general population:overlap and lack of stability overtime.Gasrtoenterology.1995;109:671-680.
[2]Harvey RF,Mauad EC,Brown AM.Prognosis in the irritable bowel syndrome:a 5-year prospective study.Lancet.1987;i:963-965.
[3]Jones R,Lydeard S.Irritable bowel syndrome in the general population.BMJ.1992,304:87-90.
[4]许国铭,李石,主编.现代消化病学(第1版)北京:人民军医出版社.1999:860.
[5]Frank L,Kleinman L,Rentz A,et al.Health-related quality of life associated with irritable bowel syndrome:comparison with other chronic diseases.Clin Ther. 2002 ,24(4):675-89.
[6]Akehurst RL,Brazier JE,Mathers N,et al.Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.Pharmacoeconomics.2002,20(7):455-62.
[7]Capurso L,Del Sette F,Ferrario F,et al.The otilonium bromide plus diazepam Versus dazepam or octylonium bromide alone in the treatment of irritable bowel syndrome:an open-conrtolled clinical trial.CurrTherRes.1992;52:368-377.
[8] Lu CL,Chen CY,Chang FY,et al.Characteristics of small bowel motility in patient s wit h irritable bowel syndrome and normal humans:an oriental study.Clinical Science.1998,95:165-169.
[9]Ritchie J.Pain from distension of the pelvic colon byinflating a balloon in the irritable colon syndrome.Gut.1973,14(2):125-32.
[10]Kozlowski CM,Green A,Grundy D,et al.the 5-HT3 ceptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetized rat.Gut.2000,46(4):474-480.
[11]Pata C,Erdal ME,Derici E,et al.Serotonin transporter gene polymorphism in irritable bowel syndrome.Am J Gastroenterol.2002,97:1780-1784.
[12]Blomhoff S,Jooobsen MB,Spetalen S,et al.Perceptual hypereactirvty to anditory stinmuli in patients with irritableboweL syndrome.Stand J Gastroenterol.2000,35(6):583-589.
[13]Greenwood-Van-Meerreld B,Gibson M,GunterW,et al.Stereotaxic delivery of cortioosterone to the amygdala modulates colonic sensitivity in rats.Brain-Ress.2001,893(12):135-142.
[14]Bakshi VP,Kalin NH.Corticot ropin-releasing hormone and animal models of anxiety:gene-environment Interactions.BiolPsychiatry,2000. 48:1175-1198.
[15]Chaudhary NA,Truelove SC.The irritable colon syndrome.A study of the clinical features,predisposing causes, and prognosis in 130 cases.Q J Med.1962,31:307-22.
[16]Neal KR,Barker L,Spiller RC.Prognosis in post-infective irritable bowel syndrome:a six year follow up study.Gut.2002,51(3):410-413.
[17]Spiller RC.Role of infection in irritable bowel syndrome.J Gastroenterol.2007,42 Suppl 17:41-47.
[18]Pimentel M,Chow EJ,I in HC.Normalization of lactulose breath testing correlates with symptom improvement in irritablebowel syndrome:a double-blind,randomized,placebo controlled study.Am J Gastroenterol.2003,98:412-419.
[19]Michael PJ,Sarah W,Michael DC.Coping st rategies and interpersonal support in patient s with irritable bowel syndrome and inflammatory bowel disease.Clinical Gast roenterology and Hepatology.2006,4(4):474-481.
[20]潘国宗,王宝恩,于中麟主编.现代消化病学进展[M].北京:北京医科大学中国协和医科大学联合出版社.1997,259.
[21]Ami DS,Michael F,Pesach S,et al.Rates of functional bowel disorders among Israeli Bedouins in rural areas compared with those who moved to permanent towns.Clinical Gast roenterology and Hepatology.2005,3(4):342-348.
[22]Simren M,Mansson A,Langkilde AM et al.Food-related gastrointestinal symptoms in the irritable bowel syndrome.Digestion.2001,63(2):108-115.
[23]Nanda R,J ames R,Smith H,et al.Food intolerance and the irritable bowel syndrome.Gut.1989,30:1099.
[24]Locke GR,Zinsmeister AR,Talley NJ,et al.Familial association in adults with functional gastrointestinal disorders.Mayo Clin Prec.2000,75(9):907-912.
[25]Levy RL,Jones KR,Whitehead WE,et al.Irritable bowel syndrome in twins:heredity and social leaming both contribute to etiology.Gastmen.terology.2001,121(4):799-804.
[26]Kanazawa M,Endo Y,Whitehead WE,et al.Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress.Digestive Diseases and Sciences.2004,49(6):1046-1053.
[1]Gralnek IM,Hays RD,Kilbourne A,The impact of irritable bowel syndrome on health-related quality of life.Gastroenterology.2004,126(7):1721-32.
[2]Hussain Z,Quigley EM.Systematic review:complementary and alternative medicine in the irritable bowel syndrome.Aliment Pharmacol Ther.2006,23(4):465-71.
[3]Whitehead WE,Levy RL,Von Korff M,et al.The usual medical care for irritable bowel syndrome.Aliment Pharmacol Ther.2004,20(11-12):1305-15.
[4]Lu W,Kaptchuk TJ,Wong H,et al.Chinese herbal medicine for irritable bowel syndrome.JAMA.1999,282(11):1035-1037.
[5]Shen YH,Nahas R.Complementary and alternative medicine for treatment of irritable bowel syndrome.Can Fam Physician.2009,55(2):143-148.
[6]Yuan R,LinY.Traditional Chinese medicine:anapProach to scientific Proof and clinical validaition.Pharmacol Ther.2000,86(2):191-198.
[7]李红妹,李鲁,沈毅.中文版SF-36用于杭州市区居民生命质量研究.中华预防医学杂志.2001,35:428-430.
[8]Patrick DL,Drossman DA,Frederick IO,et al.Quality of life in persons with irritable bowel syndrome:development and validation of a new measure.Dig Dis Sci.1998,43(2):400-411
[9]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社.2002,143.
[10]李绍芝,谭晓红.党参对小肠血流量和耗氧量的影响.中国中药杂志.1999,24(5):299-302.
[11]刘克敬,谢冬萍,李伟,等.陈皮、党参等中药对大鼠结肠肌条收缩活动的影响.山东大学学报(医学版).2003,41(1):34-36.
[12]熊元君,李晓瑾,木拉提,等.新疆党参、潞党参对肠道影响.中药药理与临床.2000,16(2):15.
[13]李伟,文红梅,崔小兵,等.白术健脾有效成分研究南京中医药大学学报.2006,22(6):366-367.
[14]Reiter M,Brandt W.relaxant effects on the tracheal and ileal smooth muscle of the guines pig.Arzneimittelforschung.1985,35(1A):408-14.
[15]张敏,高晓红,孙晓萌,等.茯苓的药理作用及研究进展.北华大学学报(自然科学版).2008,9(1):63-68.
[16]李树英.山药健脾胃作用的研究.中药药理与临床.1990,9(4):232.
[17]杨颖丽,郑天珍,瞿颂义,等.青皮和陈皮对大鼠小肠纵行肌条运动的影响.兰州大学学报(自然科学版).2001,37(5):94-97.
[18]马晓松,樊雪萍,陈忠,等.白术对离体豚鼠回肠收缩的影响.新消化病学杂.1996,4(11):603.
[19]李伟,郑天珍,瞿颂义,等.陈皮对小鼠胃排空及肠推进的影响.中药药 理与临床.2002,18(2):22-23.
[20]张晓君,祝晨曦,胡黎,等.党参多糖对小鼠免疫和造血功能的影响.中药新药与临床药理.2003,14(3):174-176.
[21]余上才,章育正,赵慧娟,等.枸杞子和白术免疫调节作用的实验研究[J].上海免疫学杂志.1994,14(1):12.
[22]李俊,梁君山,周爱武,等.白芍总苷对B淋巴细胞增殖和白介素1生成的调节作用.中国药理学与毒理学杂志.1994,8(1):53-55.
[23]张明发,沈雅琴.肉桂的药理作用及温里功效.陕西中医.1995,16(1):39-42.
[24]徐琳本,肖梅英,樊湘红.羧甲基茯苓多糖口服液的免疫作用及抗肿瘤作用研究.中成药,2000,22(3):222-223.
[25]马振亚,崇红,姚增鑫.豆类中草药对细胞免疫功能影响的实验观察.陕西中医学院学报,1979,2:3-8.
[26]唐荣江,阂照华,徐诚愈.防风的药理实验研究.中药通报,1988,13(6):45.
[27]Young HY,Luo YL,Cheng HY,et al.Analgesicand anti-inflammatory activitiesof[6]-gingerol.J Ethnopharmacol,2005,96(1-2):207.
[28]邵继红,韩珍,杨艳,等.白芍抗抑郁作用的实验研究.宁夏医学杂志.2008,30(6):193-194.
[29]韩珍,贺弋.白芍总苷的药理作用及其毒性研究进展.宁夏医学院学报.2008,30(4):538-541.
[30]王建华,催景荣.防风及其地区习用品解热镇痛作用的比较研究.中药材.1985,(1):14.
[31]张亦钦,罗凯临,赵恩和,等.中药茯苓治疗慢性精神分裂症的免疫球蛋白IgA和血清铜蓝蛋白的变化.山西医药杂志.1982,11(5):14
[32]拟健敏.浙江省肠易激综合征的流行病学和患者生活质量研究.中华内科杂志.2003,42(1):A29.
[33]Barbara G,StanghelliniV,De Giorgio R,et al.Functional gastroin testinal disorders and mast cells:implications for therapy.NeurogastroenterolMotil. 2006,18(1):6-17.
[34]Spiller R,Campbell E.Post-infectious irritable bowel syndrome.Curr Op in Gastroenterol.2007,9(5):378-384.
[35]Accarino AM,Azp iroz F,Malagelada JR.Attention and distraction:effects on gut percep tion.Gastroenterology.1997,113(2):415-422.
[36]Mayer EA,Naliboff BD,Chang L,et al.Stress and the Gastrointestinal Tract V.Stress and irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol.2001,280(4):G519-G524.
[37]Dinan TG,Quigley EM,Ahmed SM,et al.Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome:plasma cytokines as a potential biomarker?.Gastroenterology.2006,130(2):304-311.
[1]Wittmann T,Feher A,Rosztoczy A,et al.Efectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome.Orv Hetil.1999,140(9):469-473.
[2]Camilleri M,Northcutt AR,Kong S,et al.Eficacy and safety of alosetron in women with irritable bowelsyndrome:a randomized,placebo-controlled trial.Lancet.2005,355(9209):1035-1040.
[3]Battaglia G,Morseli-La bate AM,Camarri E,et al.Otiloniam bromide in irritable bowel syndrome:a double-bhnd,placebo-controlled,15-week study.Aliment Pharmacol Ther.1998,12(10):1003-1010.
[4]Jackson JL,O'Malley PG,Tomkins G,et al.Treatment of functional gastrointestinal disorders with antidepressant medications:a meta-analysis.Am J Med.2000,108(1):65-72.
[5]王敬东.脑-肠互动在肠易激综合征发病中的作用.世界华人消化杂志.2006.14:3299-3301.
[6]Pimentel M,Park S,Mirocha J,et al.The effect of anonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome:a randomized trial.Ann Intern Med.2006,45(8):557-63.
[7]吴兵,张声生.肠易激综合征腹泻型的证候学研究进展.北京中医.2007,26(5):312-314
[8]周军丽,张颖.辨证治疗IBS疗效观察.山西中医.2005,21(2):16-17
[9]彭林.辨证分型治疗泄泻型肠易激综合征58例.江西中医药.2005,36(6):27-28
[10]吴华清,姚保泰.温补脾肾法治疗腹泻型肠易激综合征疗效观察.山东中医药大学学报.2006,30(5):367-368
[11]王飞雄,袁通春.健脾补肾疏肝法治疗腹泻型肠易激综合征85例临床观察.中医药导报.2007,13(9):29-30,40
[12]潘相学,谢建群.疏肝饮治疗肠易激综合征的临床疗效观察.上海中医药大学学报.2006,20(4):48-50
[13]霍清萍,张仲伟,王兵.调肝运脾方对腹泻型肠易激综合征患者脑内兴奋区域活动的影响.上海中医药杂志.2007,41(11):40-43
[14]岳妍,张燕霞,杨强,等.清心醒脾法调节腹泻型肠易激综合征20例.中医研究.2007,20(6):48-49
[15]许海峰.逍遥散合痛泻要方治疗肠易激综合征38例.实用中医药杂志,2004,20(11):620
[16]鲍国瑞,石纶.痛泻要方合附子理中汤治疗腹泻型肠易激综合征36例临床观察.天津中医药.2008,25(1):28
[17]孙光裕,陈壁亮.匹维溴铵联合固肠止泻丸治疗腹泻为主型肠易激综合征.广东医学.2003,24(12):1365-1366
[18]兰英.痛泻要方联合黛力新治疗腹泻型肠易激综合征的疗效观察.实用医技杂志.2006,13(19):3488-3489
[19]熊秀峰.中西医结合治疗腹泻型肠易激综合征128例.河南中医.2008,28(1):58
[20]Friedel D,Thomas R,Fisher RS.Ischemic colitis during treatment with alosetron.Gastroenterology.2001,120(2):557-560.
[21]Miller DP,Alfredson T,Cook SF,Sands BE,Walker AM.Incidence of colonic ischemia,hospitalized complications of constipationand bowel surgery in relation to use of alosetron hydrochloride.Am J Gastroenterol.2003,98(5):1117-1122.
[1]Chaudhary NA,Truelove SC.The irritable colon syndrome.A study of the clinical features,predisposing causes,and prognosis in 130 cases.Q J Med.1962,31:307-22.
[2]Neal KR,Barker L,Spiller RC.Prognosis in post-infective irritable bowel syndrome:a six year follow up study.Gut.2002,51(3):410-413.
[3]Borgaonkar MR,Ford DC,Marshall JK,et al.The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection.Dig Dis Sci.2006,51(5):1026-1032.
[4]王利华,方秀才,潘国宗.肠道感染与肠易激综合征.中华内科杂志.2002,41(2):90-93.
[5]Parry SD,Stansfield R,Jelley D,et al.Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective,community-based,case-control study.Am J Gastroenterol.2003 ,98(9):1970-1975.
[6]Smith JL,Bayles D.Postinfectious irritable bowel syndrome:a long-term consequence of bacterial gastroenteritis.J Food Prot.2007,70(7):1762-9.
[7]Gerards C,Leodolter A,Glasbrenner B,et al.H.pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome.Dig Dis.2001,19(2):170-3.
[8]Soyturk M,Akpinar H,Gurler 0,et al.Irritable bowel syndrome in persons who acquired t richinellosis.Am J Gastroenterol.2007,102(5):1064-1069.
[9]Marshall JK,Thabane M,Borgaonkar MR,et al.Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen.Clin Gastroenterol Hepatol.2007,5(4):457-460.
[10]McKeown ES,Parry SD,Stansfield R,et al.Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection.Neurogastroenterol Motil.2006,18(9):839-843.
[11]Dunlop SP,Jenkins D,Spiller RC.Distinctive clinical,psychological,and histological features of postinfective irritable bowel syndrome.Am J Gastroenterol.2003,98(7):1578-83.
[12]Spence MJ,Moss-Morris R.The cognitive behavioural model of irritable bowel syndrome:a prospective investigation of patients with gastroenteritis.Gut.2007,56(8):1066-1071.
[13]Spiller RC.Role of infection in irritable bowel syndrome.J Gastroenterol.2007,42 Suppl 17:41-47.
[14]Piche T,Saint-Paul MC,Dainese R,et al.Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome.Gut.2008,57(4):468-73.
[15]Dunlop SP,Jenkins D,Neal KR,et al.Relative importance of enterochromaffin cell hyperplasia,anxiety,and depression in postinfectious IBS.Gastroenterology.2003,125(6):1651-1659.
[16]Vasiadi M,Kempuraj D,Boucher W,et al.Progesterone inhibits mast cell secretion.Int J Immunopathol Pharmacol.2006,19(4):787-794.
[17]Dizdar V,Gilja OH,Hausken T.Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia.Effect of the 5HT3-antagonist ondansetron.Neurogastroenterol Motil.2007,19(12):977-82.
[18]Kalia N,Hardcastle J,Keating C,et al.Intestinal secretory and absorptive function in Trichinella spiralis mouse model of postinfective gut dysfunction:role of bile acids.Gut.2008,57(l):41-49.
[19]Dunlop SP,Hebden J,Campbell E,et al.Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.Am J Gastroenterol.2006,101(6):1288-1294.
[20]Dunlop SP,Jenkins D,Spiller RC,et al.Distinctive clinical,psychological,and histological features of postinfective irritable bowel syndrome.Am J Gastroenterol.2003,98(7):1578-1583.
[21]Wheatcroft J,Wakelin D,Smith A,Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction.Neurogastroenterol Motil.2005,17(6):863-70。
[22]Roka R,Ait-Belgnaoui A,Salvador-Cartier,et al.Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats.Gut 2007,56(8):1072-1078.
[23]La JH,Kim TW,Sung TS,at al. Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome.J Vet Sci.2004,5(4):319-24.
[24]Gwee KA,Collins SM,Read NW,et al.Increased rectal mucosal expression of interleukin lbeta in recently acquired post-infectious irritable bowel syndrome.Gut.2003,52(4):523-526.
[25]Wang LH,Fang XC,Pan GZ.Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.Gut.2004,53(8):1096-101.
[26]Akiho H,Deng Y,Blennerhassett P,et al.Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction.Gastroenterology.2005,129(1):131-141.
[27]Rhodes DY,Wallace M.Post-infectious irritable bowel syndrome.Curr Gastroenterol Rep.2006,8(4):327-332.
[28]Cuoco L,Salvagnini M.Small intestine bacterial overgrowth in irritable bowel syndrome:a retrospective study with rifaximin.Minerva Gastroenterol Dietol.2006,52(l):89-95.
[29]Lombardo L.New insights into Lactobacillus and functional intestinal disorders. Minerva Gastroenterol Dietol.2008,54(3):287-293.
[30]Pimentel M,Chatterjee S,Chow EJ,et al.Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas:subanalysis of a double-blind randomized controlled study.Dig Dis Sci.2006,51(8):1297-1301.
[31]Halvorson HA,Schlett CD,Riddle MS,et al.Postinfectious irritable bowel syndrome--a meta-analysis.Am J Gastroenterol.2006,101(8):1894-1899.
[2]Harvey RF,Mauad EC,Brown AM.Prognosis in the irritable bowel syndrome:a 5-year prospective study.Lancet.1987;i:963-965.
[3]Jones R,Lydeard S.Irritable bowel syndrome in the general population.BMJ.1992,304:87-90.
[4]许国铭,李石,主编.现代消化病学(第1版)北京:人民军医出版社.1999:860.
[5]Frank L,Kleinman L,Rentz A,et al.Health-related quality of life associated with irritable bowel syndrome:comparison with other chronic diseases.Clin Ther. 2002 ,24(4):675-89.
[6]Akehurst RL,Brazier JE,Mathers N,et al.Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.Pharmacoeconomics.2002,20(7):455-62.
[7]Capurso L,Del Sette F,Ferrario F,et al.The otilonium bromide plus diazepam Versus dazepam or octylonium bromide alone in the treatment of irritable bowel syndrome:an open-conrtolled clinical trial.CurrTherRes.1992;52:368-377.
[8] Lu CL,Chen CY,Chang FY,et al.Characteristics of small bowel motility in patient s wit h irritable bowel syndrome and normal humans:an oriental study.Clinical Science.1998,95:165-169.
[9]Ritchie J.Pain from distension of the pelvic colon byinflating a balloon in the irritable colon syndrome.Gut.1973,14(2):125-32.
[10]Kozlowski CM,Green A,Grundy D,et al.the 5-HT3 ceptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetized rat.Gut.2000,46(4):474-480.
[11]Pata C,Erdal ME,Derici E,et al.Serotonin transporter gene polymorphism in irritable bowel syndrome.Am J Gastroenterol.2002,97:1780-1784.
[12]Blomhoff S,Jooobsen MB,Spetalen S,et al.Perceptual hypereactirvty to anditory stinmuli in patients with irritableboweL syndrome.Stand J Gastroenterol.2000,35(6):583-589.
[13]Greenwood-Van-Meerreld B,Gibson M,GunterW,et al.Stereotaxic delivery of cortioosterone to the amygdala modulates colonic sensitivity in rats.Brain-Ress.2001,893(12):135-142.
[14]Bakshi VP,Kalin NH.Corticot ropin-releasing hormone and animal models of anxiety:gene-environment Interactions.BiolPsychiatry,2000. 48:1175-1198.
[15]Chaudhary NA,Truelove SC.The irritable colon syndrome.A study of the clinical features,predisposing causes, and prognosis in 130 cases.Q J Med.1962,31:307-22.
[16]Neal KR,Barker L,Spiller RC.Prognosis in post-infective irritable bowel syndrome:a six year follow up study.Gut.2002,51(3):410-413.
[17]Spiller RC.Role of infection in irritable bowel syndrome.J Gastroenterol.2007,42 Suppl 17:41-47.
[18]Pimentel M,Chow EJ,I in HC.Normalization of lactulose breath testing correlates with symptom improvement in irritablebowel syndrome:a double-blind,randomized,placebo controlled study.Am J Gastroenterol.2003,98:412-419.
[19]Michael PJ,Sarah W,Michael DC.Coping st rategies and interpersonal support in patient s with irritable bowel syndrome and inflammatory bowel disease.Clinical Gast roenterology and Hepatology.2006,4(4):474-481.
[20]潘国宗,王宝恩,于中麟主编.现代消化病学进展[M].北京:北京医科大学中国协和医科大学联合出版社.1997,259.
[21]Ami DS,Michael F,Pesach S,et al.Rates of functional bowel disorders among Israeli Bedouins in rural areas compared with those who moved to permanent towns.Clinical Gast roenterology and Hepatology.2005,3(4):342-348.
[22]Simren M,Mansson A,Langkilde AM et al.Food-related gastrointestinal symptoms in the irritable bowel syndrome.Digestion.2001,63(2):108-115.
[23]Nanda R,J ames R,Smith H,et al.Food intolerance and the irritable bowel syndrome.Gut.1989,30:1099.
[24]Locke GR,Zinsmeister AR,Talley NJ,et al.Familial association in adults with functional gastrointestinal disorders.Mayo Clin Prec.2000,75(9):907-912.
[25]Levy RL,Jones KR,Whitehead WE,et al.Irritable bowel syndrome in twins:heredity and social leaming both contribute to etiology.Gastmen.terology.2001,121(4):799-804.
[26]Kanazawa M,Endo Y,Whitehead WE,et al.Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress.Digestive Diseases and Sciences.2004,49(6):1046-1053.
[1]Gralnek IM,Hays RD,Kilbourne A,The impact of irritable bowel syndrome on health-related quality of life.Gastroenterology.2004,126(7):1721-32.
[2]Hussain Z,Quigley EM.Systematic review:complementary and alternative medicine in the irritable bowel syndrome.Aliment Pharmacol Ther.2006,23(4):465-71.
[3]Whitehead WE,Levy RL,Von Korff M,et al.The usual medical care for irritable bowel syndrome.Aliment Pharmacol Ther.2004,20(11-12):1305-15.
[4]Lu W,Kaptchuk TJ,Wong H,et al.Chinese herbal medicine for irritable bowel syndrome.JAMA.1999,282(11):1035-1037.
[5]Shen YH,Nahas R.Complementary and alternative medicine for treatment of irritable bowel syndrome.Can Fam Physician.2009,55(2):143-148.
[6]Yuan R,LinY.Traditional Chinese medicine:anapProach to scientific Proof and clinical validaition.Pharmacol Ther.2000,86(2):191-198.
[7]李红妹,李鲁,沈毅.中文版SF-36用于杭州市区居民生命质量研究.中华预防医学杂志.2001,35:428-430.
[8]Patrick DL,Drossman DA,Frederick IO,et al.Quality of life in persons with irritable bowel syndrome:development and validation of a new measure.Dig Dis Sci.1998,43(2):400-411
[9]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社.2002,143.
[10]李绍芝,谭晓红.党参对小肠血流量和耗氧量的影响.中国中药杂志.1999,24(5):299-302.
[11]刘克敬,谢冬萍,李伟,等.陈皮、党参等中药对大鼠结肠肌条收缩活动的影响.山东大学学报(医学版).2003,41(1):34-36.
[12]熊元君,李晓瑾,木拉提,等.新疆党参、潞党参对肠道影响.中药药理与临床.2000,16(2):15.
[13]李伟,文红梅,崔小兵,等.白术健脾有效成分研究南京中医药大学学报.2006,22(6):366-367.
[14]Reiter M,Brandt W.relaxant effects on the tracheal and ileal smooth muscle of the guines pig.Arzneimittelforschung.1985,35(1A):408-14.
[15]张敏,高晓红,孙晓萌,等.茯苓的药理作用及研究进展.北华大学学报(自然科学版).2008,9(1):63-68.
[16]李树英.山药健脾胃作用的研究.中药药理与临床.1990,9(4):232.
[17]杨颖丽,郑天珍,瞿颂义,等.青皮和陈皮对大鼠小肠纵行肌条运动的影响.兰州大学学报(自然科学版).2001,37(5):94-97.
[18]马晓松,樊雪萍,陈忠,等.白术对离体豚鼠回肠收缩的影响.新消化病学杂.1996,4(11):603.
[19]李伟,郑天珍,瞿颂义,等.陈皮对小鼠胃排空及肠推进的影响.中药药 理与临床.2002,18(2):22-23.
[20]张晓君,祝晨曦,胡黎,等.党参多糖对小鼠免疫和造血功能的影响.中药新药与临床药理.2003,14(3):174-176.
[21]余上才,章育正,赵慧娟,等.枸杞子和白术免疫调节作用的实验研究[J].上海免疫学杂志.1994,14(1):12.
[22]李俊,梁君山,周爱武,等.白芍总苷对B淋巴细胞增殖和白介素1生成的调节作用.中国药理学与毒理学杂志.1994,8(1):53-55.
[23]张明发,沈雅琴.肉桂的药理作用及温里功效.陕西中医.1995,16(1):39-42.
[24]徐琳本,肖梅英,樊湘红.羧甲基茯苓多糖口服液的免疫作用及抗肿瘤作用研究.中成药,2000,22(3):222-223.
[25]马振亚,崇红,姚增鑫.豆类中草药对细胞免疫功能影响的实验观察.陕西中医学院学报,1979,2:3-8.
[26]唐荣江,阂照华,徐诚愈.防风的药理实验研究.中药通报,1988,13(6):45.
[27]Young HY,Luo YL,Cheng HY,et al.Analgesicand anti-inflammatory activitiesof[6]-gingerol.J Ethnopharmacol,2005,96(1-2):207.
[28]邵继红,韩珍,杨艳,等.白芍抗抑郁作用的实验研究.宁夏医学杂志.2008,30(6):193-194.
[29]韩珍,贺弋.白芍总苷的药理作用及其毒性研究进展.宁夏医学院学报.2008,30(4):538-541.
[30]王建华,催景荣.防风及其地区习用品解热镇痛作用的比较研究.中药材.1985,(1):14.
[31]张亦钦,罗凯临,赵恩和,等.中药茯苓治疗慢性精神分裂症的免疫球蛋白IgA和血清铜蓝蛋白的变化.山西医药杂志.1982,11(5):14
[32]拟健敏.浙江省肠易激综合征的流行病学和患者生活质量研究.中华内科杂志.2003,42(1):A29.
[33]Barbara G,StanghelliniV,De Giorgio R,et al.Functional gastroin testinal disorders and mast cells:implications for therapy.NeurogastroenterolMotil. 2006,18(1):6-17.
[34]Spiller R,Campbell E.Post-infectious irritable bowel syndrome.Curr Op in Gastroenterol.2007,9(5):378-384.
[35]Accarino AM,Azp iroz F,Malagelada JR.Attention and distraction:effects on gut percep tion.Gastroenterology.1997,113(2):415-422.
[36]Mayer EA,Naliboff BD,Chang L,et al.Stress and the Gastrointestinal Tract V.Stress and irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol.2001,280(4):G519-G524.
[37]Dinan TG,Quigley EM,Ahmed SM,et al.Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome:plasma cytokines as a potential biomarker?.Gastroenterology.2006,130(2):304-311.
[1]Wittmann T,Feher A,Rosztoczy A,et al.Efectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome.Orv Hetil.1999,140(9):469-473.
[2]Camilleri M,Northcutt AR,Kong S,et al.Eficacy and safety of alosetron in women with irritable bowelsyndrome:a randomized,placebo-controlled trial.Lancet.2005,355(9209):1035-1040.
[3]Battaglia G,Morseli-La bate AM,Camarri E,et al.Otiloniam bromide in irritable bowel syndrome:a double-bhnd,placebo-controlled,15-week study.Aliment Pharmacol Ther.1998,12(10):1003-1010.
[4]Jackson JL,O'Malley PG,Tomkins G,et al.Treatment of functional gastrointestinal disorders with antidepressant medications:a meta-analysis.Am J Med.2000,108(1):65-72.
[5]王敬东.脑-肠互动在肠易激综合征发病中的作用.世界华人消化杂志.2006.14:3299-3301.
[6]Pimentel M,Park S,Mirocha J,et al.The effect of anonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome:a randomized trial.Ann Intern Med.2006,45(8):557-63.
[7]吴兵,张声生.肠易激综合征腹泻型的证候学研究进展.北京中医.2007,26(5):312-314
[8]周军丽,张颖.辨证治疗IBS疗效观察.山西中医.2005,21(2):16-17
[9]彭林.辨证分型治疗泄泻型肠易激综合征58例.江西中医药.2005,36(6):27-28
[10]吴华清,姚保泰.温补脾肾法治疗腹泻型肠易激综合征疗效观察.山东中医药大学学报.2006,30(5):367-368
[11]王飞雄,袁通春.健脾补肾疏肝法治疗腹泻型肠易激综合征85例临床观察.中医药导报.2007,13(9):29-30,40
[12]潘相学,谢建群.疏肝饮治疗肠易激综合征的临床疗效观察.上海中医药大学学报.2006,20(4):48-50
[13]霍清萍,张仲伟,王兵.调肝运脾方对腹泻型肠易激综合征患者脑内兴奋区域活动的影响.上海中医药杂志.2007,41(11):40-43
[14]岳妍,张燕霞,杨强,等.清心醒脾法调节腹泻型肠易激综合征20例.中医研究.2007,20(6):48-49
[15]许海峰.逍遥散合痛泻要方治疗肠易激综合征38例.实用中医药杂志,2004,20(11):620
[16]鲍国瑞,石纶.痛泻要方合附子理中汤治疗腹泻型肠易激综合征36例临床观察.天津中医药.2008,25(1):28
[17]孙光裕,陈壁亮.匹维溴铵联合固肠止泻丸治疗腹泻为主型肠易激综合征.广东医学.2003,24(12):1365-1366
[18]兰英.痛泻要方联合黛力新治疗腹泻型肠易激综合征的疗效观察.实用医技杂志.2006,13(19):3488-3489
[19]熊秀峰.中西医结合治疗腹泻型肠易激综合征128例.河南中医.2008,28(1):58
[20]Friedel D,Thomas R,Fisher RS.Ischemic colitis during treatment with alosetron.Gastroenterology.2001,120(2):557-560.
[21]Miller DP,Alfredson T,Cook SF,Sands BE,Walker AM.Incidence of colonic ischemia,hospitalized complications of constipationand bowel surgery in relation to use of alosetron hydrochloride.Am J Gastroenterol.2003,98(5):1117-1122.
[1]Chaudhary NA,Truelove SC.The irritable colon syndrome.A study of the clinical features,predisposing causes,and prognosis in 130 cases.Q J Med.1962,31:307-22.
[2]Neal KR,Barker L,Spiller RC.Prognosis in post-infective irritable bowel syndrome:a six year follow up study.Gut.2002,51(3):410-413.
[3]Borgaonkar MR,Ford DC,Marshall JK,et al.The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection.Dig Dis Sci.2006,51(5):1026-1032.
[4]王利华,方秀才,潘国宗.肠道感染与肠易激综合征.中华内科杂志.2002,41(2):90-93.
[5]Parry SD,Stansfield R,Jelley D,et al.Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective,community-based,case-control study.Am J Gastroenterol.2003 ,98(9):1970-1975.
[6]Smith JL,Bayles D.Postinfectious irritable bowel syndrome:a long-term consequence of bacterial gastroenteritis.J Food Prot.2007,70(7):1762-9.
[7]Gerards C,Leodolter A,Glasbrenner B,et al.H.pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome.Dig Dis.2001,19(2):170-3.
[8]Soyturk M,Akpinar H,Gurler 0,et al.Irritable bowel syndrome in persons who acquired t richinellosis.Am J Gastroenterol.2007,102(5):1064-1069.
[9]Marshall JK,Thabane M,Borgaonkar MR,et al.Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen.Clin Gastroenterol Hepatol.2007,5(4):457-460.
[10]McKeown ES,Parry SD,Stansfield R,et al.Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection.Neurogastroenterol Motil.2006,18(9):839-843.
[11]Dunlop SP,Jenkins D,Spiller RC.Distinctive clinical,psychological,and histological features of postinfective irritable bowel syndrome.Am J Gastroenterol.2003,98(7):1578-83.
[12]Spence MJ,Moss-Morris R.The cognitive behavioural model of irritable bowel syndrome:a prospective investigation of patients with gastroenteritis.Gut.2007,56(8):1066-1071.
[13]Spiller RC.Role of infection in irritable bowel syndrome.J Gastroenterol.2007,42 Suppl 17:41-47.
[14]Piche T,Saint-Paul MC,Dainese R,et al.Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome.Gut.2008,57(4):468-73.
[15]Dunlop SP,Jenkins D,Neal KR,et al.Relative importance of enterochromaffin cell hyperplasia,anxiety,and depression in postinfectious IBS.Gastroenterology.2003,125(6):1651-1659.
[16]Vasiadi M,Kempuraj D,Boucher W,et al.Progesterone inhibits mast cell secretion.Int J Immunopathol Pharmacol.2006,19(4):787-794.
[17]Dizdar V,Gilja OH,Hausken T.Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia.Effect of the 5HT3-antagonist ondansetron.Neurogastroenterol Motil.2007,19(12):977-82.
[18]Kalia N,Hardcastle J,Keating C,et al.Intestinal secretory and absorptive function in Trichinella spiralis mouse model of postinfective gut dysfunction:role of bile acids.Gut.2008,57(l):41-49.
[19]Dunlop SP,Hebden J,Campbell E,et al.Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.Am J Gastroenterol.2006,101(6):1288-1294.
[20]Dunlop SP,Jenkins D,Spiller RC,et al.Distinctive clinical,psychological,and histological features of postinfective irritable bowel syndrome.Am J Gastroenterol.2003,98(7):1578-1583.
[21]Wheatcroft J,Wakelin D,Smith A,Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction.Neurogastroenterol Motil.2005,17(6):863-70。
[22]Roka R,Ait-Belgnaoui A,Salvador-Cartier,et al.Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats.Gut 2007,56(8):1072-1078.
[23]La JH,Kim TW,Sung TS,at al. Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome.J Vet Sci.2004,5(4):319-24.
[24]Gwee KA,Collins SM,Read NW,et al.Increased rectal mucosal expression of interleukin lbeta in recently acquired post-infectious irritable bowel syndrome.Gut.2003,52(4):523-526.
[25]Wang LH,Fang XC,Pan GZ.Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.Gut.2004,53(8):1096-101.
[26]Akiho H,Deng Y,Blennerhassett P,et al.Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction.Gastroenterology.2005,129(1):131-141.
[27]Rhodes DY,Wallace M.Post-infectious irritable bowel syndrome.Curr Gastroenterol Rep.2006,8(4):327-332.
[28]Cuoco L,Salvagnini M.Small intestine bacterial overgrowth in irritable bowel syndrome:a retrospective study with rifaximin.Minerva Gastroenterol Dietol.2006,52(l):89-95.
[29]Lombardo L.New insights into Lactobacillus and functional intestinal disorders. Minerva Gastroenterol Dietol.2008,54(3):287-293.
[30]Pimentel M,Chatterjee S,Chow EJ,et al.Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas:subanalysis of a double-blind randomized controlled study.Dig Dis Sci.2006,51(8):1297-1301.
[31]Halvorson HA,Schlett CD,Riddle MS,et al.Postinfectious irritable bowel syndrome--a meta-analysis.Am J Gastroenterol.2006,101(8):1894-1899.